Posibility of gene siliencing by siRNA in brest cancer cell lines by lipid nanoparticles
Publish place: 9th International Breast Cancer Congress
Publish Year: 1392
نوع سند: مقاله کنفرانسی
زبان: English
View: 324
نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد
- Certificate
- من نویسنده این مقاله هستم
این Paper در بخشهای موضوعی زیر دسته بندی شده است:
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
ICBCMED09_084
تاریخ نمایه سازی: 29 فروردین 1397
Abstract:
Breast cancer is the most common malignancy excluding basal and squamous cell skin cancers and the first and second-leading cause of cancer-related deaths among women in Iran and United States, respectively.Breast cancer occurs in both men and women, although male breast cancer is rare.Apoptosis (programmed cell death type I) and autophagy (type II) are crucial mechanisms regulating cell death and homeostasis. Autophagy is a type of cellular catabolic degradation response to nutrient starvation or metabolic stress.Bcl-2 is an anti-apoptotic protein that is over expressed in half of human malignancies and more than 60% of breast cancer patients which potentially leades to resistance to chemotherapy, radiation and hormone therapy-induced apoptosi.Methods: For this reason MCF-7 Cell lines were treated by home made Bcl -2 siRNA for the first time and control siRNA that was transfected with . The cells harvested at 24, 48 and 72 hours. Total RNA was extracted, and transcription level of Bcl-2 was determined by Real Time -PCR analysis. The growth curve and drug sensitivity were detected by using LDH assay test.Then this result was confirmed with immunohistochemistry. Results:According to gene expression an unknown reason caused reduction in cell number until 24 hours after transfection, then we observed up regulation of Bcl-2 mRNA level after 48hours in cell,Finally we could observe down regulation of Bcl2 transcription level in 72h compared to 48h.Conclusion:These results provided the first evidence that targeted Silencing of Bcl-2 induces autophagic cell death in MCF-7 breas cancer cells and that Bcl-2 siRNA may be used as a therapeutic strategy alone or in combination with chemotherapy in breast cancer cels that overexpress Bcl-2.
Keywords:
Authors
f jalali
shahid chamran univercity, ahvaz , Department of genetic, IRAN;
a Talaezadeh
Jundishapur University of Medical School , ahvaz ,Cancer Research Center, IRAN;
a Khodadadi
Jundishapur University of Medical School Department of Immunology,IRAN.
h Galehdari
shahid chamran univercity, ahvaz , Department of genetic, IRAN;